| Year |
Citation |
Score |
| 2010 |
Crain MJ, Chernoff MC, Oleske JM, Brogly SB, Malee KM, Borum PR, Meyer WA, Mitchell WG, Moye JH, Ford-Chatterton HM, Van Dyke RB, Seage Iii GR. Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. The Journal of Infectious Diseases. 202: 291-301. PMID 20533872 DOI: 10.1086/653497 |
0.311 |
|
| 2010 |
Tassiopoulos K, Read JS, Brogly S, Rich K, Lester B, Spector SA, Yogev R, Seage GR. Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. Aids and Behavior. 14: 1269-78. PMID 20532607 DOI: 10.1007/S10461-010-9705-0 |
0.369 |
|
| 2010 |
Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 125: e250-60. PMID 20083530 DOI: 10.1542/Peds.2009-1112 |
0.425 |
|
| 2010 |
Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, Leighty RM, Thompson B, Tuomala RE. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. Aids (London, England). 24: 109-14. PMID 19926957 DOI: 10.1097/QAD.0b013e3283323941 |
0.347 |
|
| 2009 |
Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, Thompson B, Tuomala RE, Hershow RC. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. Aids (London, England). 23: 2425-30. PMID 19617813 DOI: 10.1097/QAD.0b013e32832e34b1 |
0.35 |
|
| 2009 |
Read JS, Brogly S, Basar M, Scott G. Human immunodeficiency virus diagnostic testing of infants at clinical sites in North America: 2002-2006. The Pediatric Infectious Disease Journal. 28: 614-8. PMID 19478686 DOI: 10.1097/Inf.0B013E31819Ac33B |
0.41 |
|
| 2007 |
Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR, Oleske J, Eagle M, Van Dyke R. Reproductive health of adolescent girls perinatally infected with HIV. American Journal of Public Health. 97: 1047-52. PMID 17463385 DOI: 10.2105/AJPH.2005.071910 |
0.451 |
|
| 2007 |
Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. Aids (London, England). 21: 929-38. PMID 17457086 DOI: 10.1097/QAD.0b013e3280d5a786 |
0.302 |
|
| 2007 |
Brogly S, Read JS, Shapiro D, Stek A, Tuomala R. Participation of HIV-infected pregnant women in research in the United States. Aids Research and Human Retroviruses. 23: 51-3. PMID 17263632 DOI: 10.1089/Aid.2006.0045 |
0.38 |
|
| 2006 |
Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Archives of Pediatrics & Adolescent Medicine. 160: 778-87. PMID 16894075 DOI: 10.1001/Archpedi.160.8.778 |
0.309 |
|
| 2006 |
Brogly S, Williams P, Seage GR, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. Journal of Acquired Immune Deficiency Syndromes (1999). 41: 535-6. PMID 16652068 DOI: 10.1097/01.Qai.0000194735.66322.D9 |
0.344 |
|
| 2005 |
Brogly S, Williams P, Seage GR, Oleske JM, Van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. Jama. 293: 2213-20. PMID 15886376 DOI: 10.1001/Jama.293.18.2213 |
0.39 |
|
| 2005 |
Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Seage GR. Malignancy in perinatally human immunodeficiency virus-infected children in the United States. The Pediatric Infectious Disease Journal. 24: 237-42. PMID 15750460 DOI: 10.1097/01.Inf.0000154324.59426.8D |
0.351 |
|
| 2004 |
Bruneau J, Brogly SB, Tyndall MW, Lamothe F, Franco EL. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction (Abingdon, England). 99: 727-37. PMID 15139871 DOI: 10.1111/j.1360-0443.2004.00713.x |
0.37 |
|
| 2003 |
Brogly S, Mercier C, Bruneau J, Palepu A, Franco E. Towards more effective public health programming for injection drug users: development and evaluation of the injection drug user quality of life scale. Substance Use & Misuse. 38: 965-92. PMID 12801151 DOI: 10.1081/Ja-120017619 |
0.367 |
|
| 2002 |
Tyndall MW, Bruneau J, Brogly S, Spittal P, O'Shaughnessy MV, Schechter MT. Satellite needle distribution among injection drug users: policy and practice in two canadian cities. Journal of Acquired Immune Deficiency Syndromes (1999). 31: 98-105. PMID 12352156 DOI: 10.1097/00126334-200209010-00013 |
0.352 |
|
| 2002 |
Brogly SB, Bruneau J, Lamothe F, Vincelette J, Franco EL. HIV-positive notification and behavior changes in Montreal injection drug users. Aids Education and Prevention : Official Publication of the International Society For Aids Education. 14: 17-28. PMID 11900107 DOI: 10.1521/aeap.14.1.17.24333 |
0.442 |
|
| 2000 |
Brogly SB, Bruneau J, Vincelette J, Lamothe F, Franco EL. Risk behaviour change and HIV infection among injection drug users in Montreal. Aids (London, England). 14: 2575-82. PMID 11101070 DOI: 10.1097/00002030-200011100-00021 |
0.435 |
|
| Show low-probability matches. |